trifluoperazine has been researched along with B16 Melanoma in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nifedipine was included as the standard or reference compound." | 1.28 | In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). ( Honn, KV; Nelson, KK; Onoda, JM; Taylor, JD, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onoda, JM | 1 |
| Nelson, KK | 1 |
| Taylor, JD | 1 |
| Honn, KV | 1 |
| Ganapathi, R | 1 |
| Schmidt, H | 1 |
| Grabowski, D | 1 |
| Melia, M | 1 |
| Ratliff, N | 1 |
2 other studies available for trifluoperazine and B16 Melanoma
| Article | Year |
|---|---|
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
Topics: Animals; Calcium Channel Blockers; Cisplatin; Diltiazem; Drug Evaluation, Preclinical; Drug Resistan | 1989 |
Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Topics: Animals; Cell Survival; Doxorubicin; Drug Interactions; Drug Resistance; In Vitro Techniques; Lung N | 1988 |